Floatz logo

SL-28

Non-Small Cell Lung Carcinoma

Second Life TherapeuticsUNKNOWNPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

1127 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

SL-28 is also rated in:

intestinal cancerActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
malignant pancreatic neoplasmActive
CC
Indicative · Phase 1/2
47 / 100
View asset →
head and neck cancerActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →